Advertisement

Topics

FDA grants orphan drug designation to tesevatinib for the treatment of EGFR mutated NSLCL

06:18 EDT 8 Aug 2017 | ecancermedicalscience

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tesevatinib, an oral tyrosine kinase inhibitor, for the treatment of non-small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR)-activating...

Original Article: FDA grants orphan drug designation to tesevatinib for the treatment of EGFR mutated NSLCL

NEXT ARTICLE

More From BioPortfolio on "FDA grants orphan drug designation to tesevatinib for the treatment of EGFR mutated NSLCL"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...